Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Dec 11, 2022 3:52pm
319 Views
Post# 35164901

Onc promotional data, my read fwiw

Onc promotional data, my read fwiw

So, Onc puts out a very informative & understandable article.
Some call it self promotion ( in a derogatory context).
Perhaps the same complainers who say " management needs to communicate better".
imho that publication is great communication.
" self promotion" ?
Absolutely, something has to be done to counter the collection of hard working bashing crew.
Who at every turn possible try to discredit anything good out of onc.
For those who missed it, I'll republish later.
bottom line, it does a great jo/ at explaining the trials,the management depth,recent developments & upcoming expectations.
Not to mention the average analyst target I think near $7. With high being $15 & low being $6.
I could be wrong on numbers. Regardless, WAY more than where we are now.
BTW, all of the information oin the article is founD on company web site. With the exception of the analysts target prices.

 

<< Previous
Bullboard Posts
Next >>